Method for treating the cases of refraction amblyopia

FIELD: medicine.

SUBSTANCE: method involves introducing Mirtilene forte at a dose of 1 pill twice a day and 1% Emoxipini solution at a parabulbar dose of daily as drug therapy component in combined treatment course comprising also magnetic therapy, laser stimulation of macular retina zone and pattern-stimulation. The total treatment course is 10 days long.

EFFECT: enhanced effectiveness of treatment.

2 cl

 

The invention relates to medicine, namely to ophthalmology, and can be used for the treatment of refractive amblyopia.

There is a method of treatment of refractive amblyopia (RU # 2180821, a 61 F 9/00, 27.03.2002). The essence of the method lies in the fact that initially hold the FMS in eyeglass or contact lens for 1 week, then implanted in phakic eyes artificial lens, 3 days after implantation, a refresher course FMS in conjunction with laser pattern and stimulation of the retina within 1-2 weeks daily with breaks between methods in 1-1,5 hours Despite its positive effect on indicators of visual acuity, this method does not improve the functional status of the retina.

The closest in technical essence is a method of treatment of refractive amblyopia (RU # 2150253, a 61 F 9/00, 10.06.2000). Treatment consists of medication and homeopathic medicines that improve the blood supply to the brain, normalizes metabolic processes, relaxation of striated and smooth muscles and parallel conducting magnetic therapy, electrical stimulation of the retina and optic nerve, laserlipolysis the macular region of the retina, the pattern of stimulation, of training course, binocular and stereo vision using computer software is mm, exposure to infrared laser radiation on the ciliary muscle and relaxation of the ciliary muscle in the following way: before the eye of the patient put the lens power to +6.0 diopters, after 10 minutes reduce the power of the lens is 0.5 to 1.0 diopters, and continue to decrease the strength of your lenses every 2-3 min until the lens power to +0.5 diopters, when this procedure is carried out with simultaneous visual load.

The disadvantages of this method are a great complexity due to the large number of stages, which include several procedures, with a second course of treatment after 1-3 months. A significant disadvantage of this method is the risk of retinal detachment when conducting electrical stimulation for the treatment of amblyopia in high myopia. In addition, the known method does not have a direct action on the nervous tunic, because the flow of drugs through the overall flow, and not directly to the tissues of the eye.

The technical result of the invention consists in simplifying and shortening the treatment time, to ensure a consistent effect and visual functions.

The technical result is achieved by a method for the treatment of refractive amblyopia, including medication, concurrent therapy, laserlipolysis the macular region of the retina and pattern stimulation, otlichuy is the, as drug use Mytilene Forte oral on 1 tablet 2 times a day, 1% solution emoxipin 0.5 ml parabulbarno daily, while the course of treatment is 10 days. In addition, conduct a vitamin.

The advantages of the proposed method in comparison with the prototype is that the use of the drug Mytilene Forte stimulates the regeneration of rhodopsin, which improves the sensitivity of the light response of the retina to different levels of light emission, improvement of visual acuity in low light conditions, reduces the fragility of the capillaries, improves microcirculation in the retina. Parabulbar the introduction of a 1% solution of emoxipin strengthens the vascular wall, reduces capillary permeability, has antiaggregatory and antihypoxic action in the vessels of the eyeball, including feeding the retina. Combined application of 1% solution of emoxipin parabulbarno and Mytilene Forte oral acts on the sensory nerve cells of the retina and can achieve a stable effect of visual functions.

The method is performed as follows.

Initially conduct an adequate correction of ametropia by selection of eyeglasses, contact lenses or surgical method. Then the patient is conducting a 10-day course of treatment Le is archivename drugs: Mytilene Forte oral on 1 tablet 2 times a day, 1% solution emoxipin parabulbarno 0.5 ml daily, treat vasodilators: 1% solution of nicotinic acid in 2.0 ml, vitamin therapy: askorutin orally 1 tablet 2 times a day. Parallel to the patient undergo FMS "INFITA", also simultaneously carry out a course of laserlipolysis helium-neon laser LGN-208 B with a laser power of 0.5 mW and a wavelength of 0.64 μm. Course laserlipolysis is 10 daily sessions with the exposition 1-1,5 minutes. After a session of laserlipolysis conduct the session pattern of stimulation using the computer, using a special computer program. The treatment is carried out monoculars, in daylight, the distance from the computer monitor to the patient's eye 50 cm Before treatment to determine the optimal stimulation parameters for a particular patient (duration of presentation of the pattern, the size of the pattern element). Pattern-stimulation spend every day for 10-15 minutes each eye. Course of 10 treatments.

The method allows to achieve a stable increase of visual acuity, the formation of binocular vision, expansion of the field of view. Re-treatment can be performed after 6-12 months.

Example 1. Patient A., 14 years old was admitted with a diagnosis of OU Anisometropia OS and high Myopia, amblyopia high degree. alabi on low vision in the left eye.

History: spectacle correction does not move, picked up a contact lens on the OS to - 10.0 diopters.

OS visual Acuity without correction. = 0,02; the contact lens to - 10.0 diopters. = 0,2

the threshold electric sensitivity 100 µa

electrical lability 29.0 Hz

nature vision binocular with 4 meters

the Doppler indices: average linear flow velocity in the ophthalmic artery of 14.4 cm/s

The treatment by the proposed method. The patient spent a 10-day course of drug treatment Mytilene Forte oral on 1 tablet 2 times a day, parabulbar the introduction of a 1% solution of emoxipin 0.5 ml daily, also treated in a/m the introduction of a 1% solution of nicotinic acid in 2.0 ml: askorutin orally 1 tablet 2 times a day. Simultaneously conducted daily rate FMS using a pulsed low frequency physiotherapy apparatus of INFITA" with prefix OPTIMAS. The effects of pulsed low-frequency electromagnetic field passes through the spectacle frame and the emitter within 8 minutes daily for 10 days. Parallel to the patient daily conducted a 10-day course of laserlipolysis helium-neon laser LGN-208 B with a laser power of 0.5 mW and a wavelength of 0.64 μm, the exposure time was 1-1,5 minutes. After a session of laserlipolysis conduct session p is ternay stimulation using the computer, using a special computer program. The treatment is carried out monoculars, in daylight, the distance from the computer monitor to the patient's eye 50 cm Before treatment to determine the optimal stimulation parameters for a particular patient (duration of presentation of the pattern, the size of the pattern element). Pattern-stimulation spend every day for 10-15 minutes each eye. Course of 10 treatments.

At discharge: OS visual Acuity without correction. = 0,04;

in the contact lens to - 10.0 diopters. = 0,3

the threshold electric sensitivity 90 µa

electrical lability of 28.0 Hz

nature vision binocular with 4.5-5 meters

field of vision increased by 5 gr.

the Doppler indices: average linear flow velocity in the ophthalmic artery 16.9 cm/s

Example 2. Patient S., 11 years old was admitted with a diagnosis of OU Anisometropia OD the high degree of Hyperopia, amblyopia high degree.

Complaints about low vision right eye.

History: spectacle correction does not move, picked up a contact lens on the OD to +6.0 diopters.

OD visual Acuity without correction. = 0,09;

in the contact lens to +6.0 diopters. = 0,3

the threshold electric sensitivity 90 µa

electrical lability of 28.0 Hz

nature vision binocular with 4.5 meters

the Doppler indices: average linear flow velocity in the ophthalmic art is the history of 14.9 cm/s

The treatment by the proposed method. The patient spent a 10-day course of drug treatment Mytilene Forte oral on 1 tablet 2 times a day, parabulbar the introduction of a 1% solution of emoxipin 0.5 ml daily, also treated in a/m the introduction of a 1% solution of nicotinic acid in 2.0 ml: askorutin orally 1 tablet 2 times a day. Simultaneously conducted daily rate FMS using a pulsed low frequency physiotherapy apparatus of INFITA" with prefix OPTIMAS. The effects of pulsed low-frequency electromagnetic field passes through the spectacle frame and the emitter within 8 minutes daily for 10 days. Parallel to the patient daily conducted a 10-day course of laserlipolysis helium-neon laser LGN-208 B with a laser power of 0.5 mW and a wavelength of 0.64 μm, the exposure time was 1-1,5 minutes. After a session of laserlipolysis conduct the session pattern of stimulation using the computer, using a special computer program. The treatment is carried out monoculars, in daylight, the distance from the computer monitor to the patient's eye 50 cm Before treatment to determine the optimal stimulation parameters for a particular patient (duration of presentation of the pattern, the size of the pattern element). Pattern-stimulati who spend every day for 10-15 minutes each eye. Course of 10 treatments.

At discharge: OD visual Acuity without correction = 0,1

in the contact lens to +6.0 diopters. = 0,5

the threshold electric sensitivity 80 µa

electrical lability of 27.0 Hz

nature vision binocular with 5 meters

field of vision increased by 5-7 gr.

the Doppler indices: average linear flow velocity in the ophthalmic artery of 18.1 cm/s

Thus, the clinical results show that the proposed method of treatment of refractive amblyopia allows it to achieve its objectives, namely: to improve visual acuity, increase the field of vision, improve hemodynamic parameters (data Doppler studies), functional status of the retina (electroacoustically, electromobility).

1. The method of treatment of refractive amblyopia, including medication, concurrent therapy, laserlipolysis the macular region of the retina and pattern stimulation, characterized in that the quality of medicines use Mytilene Forte oral on 1 tablet 2 times a day, 1% solution emoxipin 0.5 ml parabulbarno daily, while the course of treatment is 10 days.

2. The method according to claim 1, characterized in that it further conduct of the vitamin.



 

Same patents:

FIELD: medicine, in particular ophthalmology.

SUBSTANCE: invention relates to method for eyes protection form damaging action of tear agents. More particularly, anesthetic and anti-histamine agent are subsequently dropped in eye, filament probe is carried out and when anesthesia is not full anesthetic agent is dropped again.

EFFECT: new method for eyes protection form action of tear agents.

2 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention represents a pharmaceutical tablet comprising a core and bound envelope wherein (a) core comprises solid particles of water-soluble dye dispersed in matrix, and (b) envelope comprises hellanic gum. Due to the presence of water-soluble dye in the tablet core it shows spotted shape that provides easy recognition of the tablet. The tablet is useful for peroral and intraoral administration.

EFFECT: improved and valuable properties of tablet.

30 cl, 6 ex

FIELD: medicine.

SUBSTANCE: method involves administering drugs usable for hindering keratoleukoma occurring after carrying out excimer laser keratectomy with an antioxidant agent being added. The agent is used for jet irrigating cornea before setting lens.

EFFECT: enhanced effectiveness in reducing lipid peroxidation products quantity; accelerated cornea epithelialization.

2 cl, 2 tbl

FIELD: medicine.

SUBSTANCE: invention proposes a method for inhibition of chorionic neovascularization. Method involves irradiation of undesirable novel vascular reticulum in combination with photosensitive agent (porphyrine) and an anti-angiogenic agent taken among antagonist of phospholipase A2, inhibitor of complex kappa B, inhibitor of the growth hormone, inhibitor of insulin-like growth factor-1, inhibitor of cyclooxygenase II, inhibitor of protein kinase C (stautosporin PKC 412) and inhibitor of angiotensin II. The claimed combined treatment provides potentiation of effect of adjunctive photodynamic therapy in combination with enhanced safety.

EFFECT: improved treatment method.

7 cl

FIELD: medicine, ophthalmology.

SUBSTANCE: as the main preparation it is necessary to apply "Prospidin" to keep and improve visual functions. The innovation suggested is considered to be more available and cheaper for patients against other well-known methods.

EFFECT: higher efficiency of therapy.

3 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: one should daily introduce medicinal mixture consisting of lidocaine, retiling, dalargin, mildronate and lidase into orbital lymphatic area, about 8-10 procedures/course followed by discrete plasmapheresis by activating cell mass due to incubation with mexidole and irradiating with ultraviolet in the course of re-infusion. The innovation provides improved visual functions due to correcting biochemical and microcirculatory disorders.

EFFECT: higher efficiency of therapy.

1 cl, 2 ex

FIELD: medicine.

SUBSTANCE: method involves administering bee-stinging procedures on cervical collar zone symmetrically relative to vertebral column every other day. The number of stings is even being equal to 2-10 during the 1-9 days long time period. Ten stings per session are prescribed beginning from the eleventh day to the treatment end. The total treatment course involves 50-70 stings with bee sting being removed in 15-20 min from the beginning of stinging.

EFFECT: enhanced effectiveness in repairing vision function.

FIELD: veterinary ophthalmology.

SUBSTANCE: the present innovation deals with treating infectious-inflammatory ocular diseases in cattle due to complex treatment with applying antibiotic preparation and biolan, moreover, antibiotic should be introduced into parotid lymphatic center through catheter once or twice daily at the quantity of about 8-10 ml, and biolan - at the dosage of 3-10 mg into the lower conjunctival arch of an eyeball. Such a technique due to taking into account optimal conditions of intraocular liquid circulation provides synergistic effect of the preparations introduced.

EFFECT: higher efficiency of therapy.

1 cl, 1 ex

FIELD: medicine, in particular angiogenesis prophylaxis and treatment.

SUBSTANCE: invention relates to 2-cyclooxygenase inhibitors selected from group containing 4-[5-(4-chlorophenyl)-3-phenyl-1H-pyrazole-1-yl] benzenesulfonamide; 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazole-1-yl] benzenesulfonamide; 4-[5-methyl-3-phenyloxazole-4-yl] benzenesulfonamide or pharmaceutically acceptable salts thereof and pharmaceutical composition containing the same in therapeutically effective amount. Said composition are useful in treatment and/or prophylaxis of angiogenesis disorders such as metastasis, eye angiogenesis, diabetic retinopathy, etc. in subjects are needed in such treatment and/or prophylaxis.

EFFECT: new pharmaceuticals for angiogenesis treatment and/or prophylaxis.

5 cl

FIELD: medicine, ophthalmology.

SUBSTANCE: the present innovation deals with conservative treatment of corneal, retinal and optic nerve's diseases. It includes depositing in ocular tissues of medicinal preparation upon cellular mass. For this purpose it is necessary to apply erythrocytic mass isolated out of a patient to saturate it with medicinal preparation at the ratio of 1:1 due to incubating this mixture at 22-25° C for 20 min. The mixture should be injected into ocular tissues at the nearest distance against pathological focus once/5 d. In case of corneal lesions erythrocytic mass-based preparation should be injected under bulbar conjunctiva perilimbically at the quantity of 0.2-0.3 ml, and at retinal lesions and those of patient's optic nerve - parabulbarly and retrobulbarly at the quantity of 1.0 ml, moreover, medicinal preparation should be chosen out of the following group of solutions: 0.3% gentamicin, or 0.25% derinate, or 1% emoxipine, or 4% taufone. The method is low invasive, of lower immunoreactivity and enables to shorten the terms for inactivation of erythrocytes saturated with medicinal preparation by depositing it at maximal distance against pathological focus.

EFFECT: higher efficiency.

2 ex

FIELD: cosmetology, esthetic surgery, applied biopharmacology.

SUBSTANCE: invention relates to medicative and cosmetic agents, and uses of biologically active substances based on natural biological complexes. Claimed method includes application of Mirralgin balm having analgesic, anti-inflammation and resolving action, Reventon balm, having vessel restorative action, for edema reducing and microcirculation improving. In process of blepharoplastic eye boundary bandage microemulsion having recovery and animative action on eaves skin is applied, and in process of facelifting cream mask having bactericide, vessel restorative and recovering action, and enhancing of local immunity is applied. Mirralgin balm and Reventon balm treatment is carried out sequentially or alternatively. In another embodiment after skin cleaning and treatment of damaged zone with anti-septic agent Bacteriophage gel, which disinfects skin surface, prevents biofilm forming, accelerates cicatrizing process is applied, then posttraumatic zone is treated with cleaning milk, toned up with tonic lotion and cream mask having bactericide, vessel restorative and recovering action, and enhancing of local immunity is applied.

EFFECT: method for skin structure recovering without skin trauma.

4 cl, 7 ex, 1 tbl

FIELD: cosmetology, esthetic surgery, applied biopharmacology.

SUBSTANCE: invention relates to medicative and cosmetic agents, and uses of biologically active substances based on natural biological complexes. Claimed method includes application of Mirralgin balm having analgesic, anti-inflammation and resolving action, Reventon balm, having vessel restorative action, for edema reducing and microcirculation improving. In process of blepharoplastic eye boundary bandage microemulsion having recovery and animative action on eaves skin is applied, and in process of facelifting cream mask having bactericide, vessel restorative and recovering action, and enhancing of local immunity is applied. Mirralgin balm and Reventon balm treatment is carried out sequentially or alternatively. In another embodiment after skin cleaning and treatment of damaged zone with anti-septic agent Bacteriophage gel, which disinfects skin surface, prevents biofilm forming, accelerates cicatrizing process is applied, then posttraumatic zone is treated with cleaning milk, toned up with tonic lotion and cream mask having bactericide, vessel restorative and recovering action, and enhancing of local immunity is applied.

EFFECT: method for skin structure recovering without skin trauma.

4 cl, 7 ex, 1 tbl

FIELD: cosmetology, in particular cosmetic and/or dermatological agents.

SUBSTANCE: claimed emulsion contains perfluorocarbons, water, oil phase and emulsifier. Additionally oil phase contains essential oil as agent for increased oxygen utilization by skin. Emulsion of present invention allows skin saturation with oxygen and expedites oxygen utilization interruption by skin.

EFFECT: emulsion increasing oxygen utilization rate in all epidermis layers.

4 cl, 1 ex, 1 tbl, 3 dwg

FIELD: cosmetology, in particular cosmetic and/or dermatological agents.

SUBSTANCE: claimed emulsion contains perfluorocarbons, water, oil phase and emulsifier. Additionally oil phase contains essential oil as agent for increased oxygen utilization by skin. Emulsion of present invention allows skin saturation with oxygen and expedites oxygen utilization interruption by skin.

EFFECT: emulsion increasing oxygen utilization rate in all epidermis layers.

4 cl, 1 ex, 1 tbl, 3 dwg

FIELD: spatial engineering.

SUBSTANCE: method of preparing freely standing spatial formulation containing liquid carrier, wherein solidification agent is dispersed, involves pumping formulation at temperature allowing introduction of formulation into inlet of tube, which also has outlet and is provided with cooling device so that formulation is discharged through tube outlet in freely standing state.

EFFECT: simplified procedure allowing utilization thereof for a variety of products.

27 cl, 3 dwg, 3 tbl

FIELD: medicine.

SUBSTANCE: invention relates to brown algae-based medicative and prophylaxis preparation for treatment of periodontum inflammations. Claimed composition contains extract obtained from Ascophylum nodosum and Fucus vesiculous algae and water in the next mass ratio (gram): extract 1: water 100.

EFFECT: preparation stimulating lactobacterium production and not causing mouth cavity dysbacteriosis.

23 tbl

FIELD: veterinary.

SUBSTANCE: one should preliminarily dissolve 0.1 g sodium selenite dried up to constant weight in glycerol at phase ratio being 1:10 at heating at water bath at 60° C, or at phase ratio being 1:20 at 20° C at mixing, then the obtained solution should be supplemented with 100 g corn germs oil at constant mixing to obtain homogeneous solution. The innovation could be applied to obtain preparation for regulating metabolic processes in animal bodies. The method provides remedy containing natural biologically active complexes to enhance its antioxidant action.

EFFECT: higher efficiency.

FIELD: medicine, in particular agent for hand cleaning without water application.

SUBSTANCE: claimed agent contains polyvinyl alcohol bearing 8-13 of acetate groups and having dynamic viscosity from 23 to 47 Pa.c.103, or mixture of polyvinyl alcohol bearing 0.8-2.0 of acetate groups and having dynamic viscosity from 17 to 25 Pa.c.103 with polyvinyl alcohol bearing 8-13 of acetate groups and having dynamic viscosity from 16 to 19 Pa.c.103 in ratio of 1:(0.4-1.5), ethanol and water. Additionally agent contains PEG-40 and hydrogenised castor oil in specific ratio (mass %).

EFFECT: agent for hand cleaning applicable at minus temperatures without losses of consumption properties.

8 cl, 2 ex

FIELD: antiperspirant deodorant products.

SUBSTANCE: claimed product contains salt with antiperspirant activity and water soluble polymer, containing Bronsted acids, which acts as co-thickener when blending with antiperspirant salt in presence of water. Before application polymer is physically divided from antiperspirant salt.

EFFECT: antiperspirant product of improved effectiveness.

21 cl, 7 ex, 7 tbl

FIELD: cosmetology, in particular skin care products.

SUBSTANCE: claimed agent contains bioactive components, namely albumin, placenta hydrolyzate, and sodium alginate. Additionally it may contain target additives, glycerol and essential oils. All components are used in specific qualitative ratio.

EFFECT: cosmetic product of antimicrobial, moistening, stimulating, antiallergic, and sorption action, capable of stimulation repairer and smoothing processes.

2 cl, 8 ex

FIELD: medicine.

SUBSTANCE: method involves applying antiherpetic therapy using Phamcyclovir. Then, Trental is sequentially introduced during 5 days with 2-5 ml of cerebrolysin being concurrently intratissularly introduced behind mastoid process tip. Mexidol is administered for 10 days. The treatment is finished by introducing Polyoxydonium.

EFFECT: combined microcirculation improvement; high neurotrophic and antioxidant activity; secondary immune deficiency adjustment; eliminated labyrinth hydrops.

Up!